Genetic influences on the response to warfarin

Purpose of reviewWarfarin has a narrow therapeutic index and there is wide interindividual variability in the drug dose requirement. Uncertainty of response renders currently used loading regimens inaccurate as they fail to take into account individual patient factors that have a major influence on anticoagulation response. This review focuses on recent research findings demonstrating the impact of genetics on warfarin sensitivity and dose requirement and the issues concerning the clinical utility of individualized therapy. Recent findingsSingle-nucleotide polymorphisms in cytochrome P450 2C9 and vitamin K epoxide reductase have been shown to make significant contributions to the variability in warfarin dose requirements. Polymorphisms in other genes that mediate the actions of warfarin make little or no contribution to the variability. Racial and cultural differences influence dose requirements, which can be explained at least in part by genetic and dietary factors. SummaryIndividualization of therapy based on genetic and environmental factors has the potential to reduce the adverse effects associated with the commencement of warfarin therapy. Prospective studies that incorporate both CYP2C9 and VKORC1 genes and environmental factors in warfarin dose calculation will be required to demonstrate the safety, cost-effectiveness, and feasibility of individualized dosing regimens.

[1]  M. Shearer,et al.  Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1 , 2004, Thrombosis and Haemostasis.

[2]  M. Matsuoka.  [Coagulation factors]. , 1961, Jibi inkoka Otolaryngology.

[3]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[4]  O. Wallerman,et al.  Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors , 2004, The Pharmacogenomics Journal.

[5]  M. Shearer,et al.  Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. , 1993, The American journal of clinical nutrition.

[6]  R. Sainsbury,et al.  Evaluation of a warfarin initiation protocol for older people , 2003, Internal medicine journal.

[7]  A. Hofman,et al.  Patients with an ApoE e4 allele require lower doses of coumarin anticoagulants , 2005 .

[8]  S. Hunt,et al.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.

[9]  Andreas Fregin,et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.

[10]  F. Kamali,et al.  Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin , 2004, Clinical pharmacology and therapeutics.

[11]  I. Ieiri,et al.  Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. , 2003, Blood.

[12]  M. Charng,et al.  A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. , 2005, Human molecular genetics.

[13]  S. Moriya,et al.  Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. , 2005, Life sciences.

[14]  L. Wienkers,et al.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.

[15]  D. P. Bentley,et al.  Flexible induction dose regimen for warfarin and prediction of maintenance dose. , 1984, British medical journal.

[16]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[17]  E. Spina,et al.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance , 2002, Clinical pharmacology and therapeutics.

[18]  Y. Lim,et al.  Novel CYP2C9 genetic variants in asian subjects and their influence on maintenance warfarin dose , 2004, Clinical pharmacology and therapeutics.

[19]  T. Wienker,et al.  VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation , 2005, Thrombosis and Haemostasis.

[20]  A. Khvorova,et al.  Identification of the gene for vitamin K epoxide reductase , 2004, Nature.

[21]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[22]  S. Hutson,et al.  Assembly of the Warfarin-sensitive Vitamin K 2,3-Epoxide Reductase Enzyme Complex in the Endoplasmic Reticulum Membrane* , 1997, The Journal of Biological Chemistry.

[23]  J. Hambleton,et al.  The Influence of Ethnicity on Warfarin Dosage Requirement , 2005, The Annals of pharmacotherapy.

[24]  H. Halkin,et al.  Common Genetic Variants of Microsomal Epoxide Hydrolase Affect Warfarin Dose Requirements Beyond the Effect of Cytochrome P450 2C9 , 2005, Clinical pharmacology and therapeutics.

[25]  H. Echizen,et al.  Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patients , 2003, Clinical pharmacology and therapeutics.

[26]  R. Kim,et al.  CYP2C9 allelic variants: ethnic distribution and functional significance. , 2002, Advanced drug delivery reviews.

[27]  K. Hampton,et al.  A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. , 2000, Age and ageing.

[28]  M. Wadelius,et al.  Warfarin dose related to apolipoprotein E (APOE) genotype , 2005, European Journal of Clinical Pharmacology.

[29]  J. Breslow,et al.  Human apolipoprotein E isoprotein subclasses are genetically determined. , 1981, American journal of human genetics.

[30]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[31]  Howard L McLeod,et al.  Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype , 2005, Thrombosis and Haemostasis.

[32]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[33]  A. Hofman,et al.  Patients with an ApoE ϵ4 allele require lower doses of coumarin anticoagulants , 2005, Pharmacogenetics and genomics.

[34]  M. Caldwell,et al.  A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. , 2005, Clinical medicine & research.

[35]  A. Mrhar,et al.  Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose , 2005, The Pharmacogenomics Journal.

[36]  D. Stafford,et al.  A Missense Mutation in γ-Glutamyl Carboxylase Gene Causes Combined Deficiency of All Vitamin K-Dependent Blood Coagulation Factors , 1998 .

[37]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[38]  J. Jespersen,et al.  Multicentre randomised study of computerised anticoagulant dosage , 1998, The Lancet.

[39]  D. Stafford,et al.  A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors. , 1998, Blood.

[40]  W. Trager,et al.  Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. , 1996, Archives of biochemistry and biophysics.

[41]  C. Vermeer,et al.  Novel mutation in the γ-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K–dependent blood coagulation factors , 2000 .

[42]  S. Moriya,et al.  Ethnic differences in CYP 2 C 9 * 2 ( Arg 144 Cys ) and CYP 2 C 9 * 3 ( Ile 359 Leu ) genotypes in Japanese and Israeli populations , 2005 .